13 October 2025 Sydney, Australia

Nyrada Selects Accelagen as CRO for Phase IIa Clinical Trial

Highlights:

- Nyrada has appointed Accelagen as Contract Research Organisation (CRO) for its Phase IIa clinical trial evaluating Xolatryp as a potential treatment for patients with acute myocardial infarction (AMI).
- Subject to Human Research Ethics Committee (HREC) approval, Nyrada remains on track to commence patient dosing in the first quarter of the 2026 calendar year.

Nyrada Inc (ASX:NYR), a clinical-stage biotechnology company developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today announces its appointment of a Contract Research Organisation (CRO) to oversee its Phase IIa clinical trial.

In July 2025, Nyrada announced plans to commence a Phase IIa clinical trial to assess the safety and preliminary efficacy of Xolatryp in patients with ST-Elevation Myocardial Infarction (STEMI) who undergo primary Percutaneous Coronary Intervention (PCI). The trial will evaluate Xolatryp as a first-in-class intravenous treatment to reduce myocardial injury following ischemia.

Nyrada has appointed Accelagen as Contract Research Organisation (CRO) to oversee this trial. Accelagen is headquartered in Melbourne, Australia.

Nyrada plans to submit is Human Research Ethics Committee (HREC) application for the Phase IIa clinical trial in the December 2025 quarter and, pending approval, remains on track to commence patient dosing in the first quarter of the 2026 calendar year.

About Xolatryp™

Xolatryp (formerly known as NYR-BI03) is a small-molecule inhibitor of TRPC 3/6/7 channels designed to limit pathological Ca^{2+} entry, protect mitochondrial function, and reduce ischemia reperfusion injury associated with AMI.

A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics was successfully completed and a Phase IIa clinical trial to assess safety and preliminary efficacy is scheduled to commence in the first quarter of 2026 calendar year, enrolling patients with AMI who undergo primary PCI.

– ENDs –

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company developing innovative small-molecule treatments, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both cardioprotection and neuroprotection, and has completed a healthy volunteer Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by John Moore, Non-Executive Chair, on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.